Companies › Uniquity One (UNI)
2 active drug programs in 3 registered trials: 3 Phase 2; Respiratory, Gastroenterology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Solrikitug IL-4 receptor alpha inhibitor | IL4R | Phase 2 | COPD; Eosinophilic Esophagitis (EoE) | Feb 2027 |
| Solriktug (NSI-8226) | – | Phase 2 | Asthma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06496607 | Solriktug (NSI-8226) | Phase 2 | Asthma | Respiratory | Jul 2026 |
| NCT06496620 | Solrikitug | Phase 2 | COPD | Respiratory | Feb 2027 |
| NCT06598462 | Solrikitug | Phase 2 | Eosinophilic Esophagitis (EoE) | Gastroenterology | Apr 2027 |
Apogee Therapeutics Guangdong Hengrui Pharmaceutical Sanofi Keymed Biosciences Co.Ltd Regeneron Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Innovent Biologics (Suzhou) Jiangsu Genscend Biopharmaceutical Genrix (Shanghai) Biopharmaceutical
Connect Biopharm Aqualung Therapeutics Shanghai Novamab Biopharmaceuticals PPD Development, LP Upstream Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.